Panacea Biotec director Shantanu Yeshwant Nalavadi resigns
Pursuant to Regulation 30(2) read with Para A of Part A of Schedule III ofthe SEBI Regulations, 2015, we would like to inform that Mr. Shantanu Yeshwant Nalavadi, Non-Executive Nominee Director of the Company has, due to his professional commitments, tendered resignation from the Board of Directors of the Company vide his letter dated March 10, 2022.
New Delhi: Pursuant to Regulation 30(2) read with Para A of Part A of Schedule III ofthe SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that Mr. Shantanu Yeshwant Nalavadi, Non-Executive Nominee Director of the Company has, due to his professional commitments, tendered resignation from the Board of Directors of the Company vide his letter dated March 10, 2022. Mr. Shantanu Yeshwant Nalavadi was earlier nominated by Vistra ITCL (India) Limited acting as Debenture Trustee with respect to non-convertible debentures issued to India Resurgence Fund-Scheme 1, India Resurgence Fund-Scheme 2 and Piramal Enterprises Limited which have been fully redeemed on March 03,2022. The said resignation has become effective from March 10, 2022. You are requested to take the above information on record.
Read Also - Panacea Biotec gets CDSCO nod Pentavalent vaccine for 5 deadly disease
Panacea Biotec is an Innovation driven Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals, Vaccines and Biosimilars.
Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited with a commitment to make Innovative Products Affordable and Accessible to the masses. It got publically listed on Indian National Stock Exchanges in September 1995 as Panacea Biotec Ltd.
Panacea Biotec is witnessing a period of expansion across every aspect of our business from innovative products to customers in market, from manufacturing to regulatory approvals and thereby laying the foundation for translation of our vision in becoming greatest, largest and most admired biotechnology company in the World by 2020.
Ardent Research and Development efforts have always been a great strength of Panacea Biotec. The main research areas are New Chemical Entities (NCE), New Biological Entities (NBE) Novel Drug Delivery System (NDDS) based pharmaceutical formulations, Novel peptides & human monoclonal antibodies and Vaccine development. The company has developed four distinguished, ultra-modern, state-of-art R&D centres in different locations, having internal capabilities for constant research, with over 300 highly professional and skilled scientists engaged in various aspects of research.
Read Also - Panacea Biotec, CEPI, THSTI partner to develop broadly protective Betacoronavirus vaccines
